Our findings present both pathophysiological and therapeutic implications for understanding the role of ENT3 in erythroid biology and treating anemia observed in several human genetic disorders occurring due to mutations in hENT3 or nucleoside analog-based drug therapy. This evidence concerns the gene SLC29A3 and anemia.